TruScreen hints at increased sales in the new year

TruScreen hints at increased sales in the new year
TruScreen's device tests women for cervical cancer. (Image: Supplied)
Jonah Franke-Bowell
New Zealand Exchange-listed cervical cancer testing company TruScreen told the market on Tuesday morning that demographic shifts in the global south are helping it. The expansion of publicly administered gynaecological health programmes in rapidly developing countries such as Vietnam, Indonesia, Mexico, Uzbekistan and China portend increased sales volumes for the company early next year as healthcare providers worldwide start filling order books.“TruScreen is at the turning point of its commercialisation phase. Sales have been increa...